^
Association details:
| Biomarker: | SPARC overexpression |
|---|---|
| Cancer: | Pancreatic Adenocarcinoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + gemcitabine (DNA synthesis inhibitor) + albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Published date:
10/16/2023
Excerpt:
High expression of STAT3, ACTA2, and SPARC was associated with significant mOS benefit in patients who received GCN.
